ArticleAllergy, asthma & immunology research2026
Impact of Health Insurance Type on Access to Biologics and Systemic Corticosteroid Exposure in Patients With Severe Asthma: A Real-World Study From the Korean Severe Asthma Registry (KoSAR).
Article in Allergy, asthma & immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeThe impact of socioeconomic status on asthma control has been widely investigated. However, evidence regarding the impact of health insurance type on biologic utilization and systemic corticosteroid (SCS) exposure among patients with severe asthma remains limited. This study aimed to evaluate the associations between health insurance type, biologic utilization, and SCS dose in South Korea.
methodsData from the Korean Severe Asthma Registry (KoSAR) between March 2022 and October 2023 were analyzed. Patients were categorized into 4 different groups based on their health insurance type: National Health Insurance (NHI) with private health insurance (PHI), NHI-only, and Medical Aid (MA) with PHI, and MA-only.
resultsAmong the 578 patients with severe asthma, 327 (56.6%) were classified as NHI+PHI, 192 (33.2%) as NHI-only, 22 (3.8%) as MA+PHI, and 37 (6.4%) as MA-only. Decline in lung function, asthma exacerbations, and impaired quality of life were significantly more prevalent in the MA+PHI and MA-only groups. Overall, 159 patients (27.5%) were identified as biologic users. The most frequently prescribed biologics were dupilumab (8.8%), reslizumab (8.5%), omalizumab (7.1%), followed by mepolizumab (2.3%). Biologic utilization varied significantly by insurance type, with rates of 30.9% in the NHI+PHI group, 27.1% in the NHI-only group, and only 8.1% in the MA-only group (
conclusionsOur study showed that differences in biologic and SCS use were associated with insurance type. These findings suggest that insurance coverage and out-of-pocket expenses are important factors influencing access to optimal care for severe asthma, emphasizing the need for policy interventions to promote health equity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.